Skip to main content
2022 Guide to Patient Support Services


2022 Oncology Guide to Patient Support Services

Exelixis Access Services


Exelixis Access Services (EASE) includes programs designed to support patients who are prescribed Exelixis oncology drugs Cabometyx or Cometriq (Table).

EASE Programs

The EASE programs are drug-specific and provide financial, access, and reimbursement support for eligible patients.

Cabometyx 15-Day Free Trial Program

The 15-Day Free Trial Program provides free drug to help patients start Cabometyx treatment quickly.

  • Limited to on-label indications
  • Must be new prescription
  • Restrictions and eligibility rules apply.

To request this program only, complete the 15-day Free Trial Request Form.

Cabometyx Quick Start Program

The Quick Start Program provides free drug to eligible patients who experience a payer decision delay of 5 days or more.

  • Limited to on-label indications
  • Additional restrictions and eligibility rules apply.

Cabometyx Dose Exchange Program

The Dose Exchange program provides a free 15-tablet supply of Cabometyx in the lower dose to help patients who require a dose reduction.

  • Patients are required to return any unused product
  • Additional restrictions and eligibility rules apply.

EASE Co-Pay Program

Eligible patients with commercial insurance will pay $0 per month for Cabometyx or Cometriq, for a maximum benefit of $25,000 per year.

  • Patients with government insurance are excluded
  • Additional eligibility restrictions apply.

EASE Patient Assistance Program

Eligible patients who are uninsured or are insured but cannot afford the cost of the medication may receive Cabometyx or Cometriq free of charge.

TABLE Exelixis Oncology Drugs

Patient support programs

Cometriq (cabozantinib) capsules
Treatment of progressive, metastatic medullary thyroid cancer
Patient support programs

Cabometyx (cabozantinib) tablets Indications

Treatment of patients with advanced renal-cell carcinoma (RCC); first-line treatment of patients with advanced RCC in combination with nivolumab; treatment of patients with hepatocellular carcinoma who have been previously treated with sorafenib; treatment of adult and pediatric patients aged ≥12 years with locally advanced or metastatic differentiated thyroid cancer that has progressed following prior vascular endothelial growth factor receptor–targeted therapy and who are radioactive iodine-refractory or ineligible

Report Broken Links

Have you encountered a problem with a URL (link) on this page not loading correctly or is displaying an error message?

Help us fix it! Report broken links here.

Report Broken Links

Report Broken Links

*OPM Webpage
Please copy the URL (link) of the OPM webpage you are currently on.
*Broken Link
Please copy the URL (link) to the external webpage that is not displaying content correctly.
Errors include, but are not limited to:
  • "This site can’t be reached"
  • "Hmm. We’re having trouble finding that site."
  • "Hmmm… can't reach this page"
  • "404 Error: Page not found"